Contineum Therapeutics (CTNM) CSO trades stock under 10b5-1 plan

Rhea-AI Filing Summary

Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. exercised stock options and sold a small block of shares. On February 11, 2026, he exercised options for 400 shares of Class A common stock at $1.01 per share and then sold 400 shares at $16 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he directly owned 156,052 shares of Class A common stock and held 75,530 stock options, with an additional 6,842 shares held indirectly by his spouse.

Insider Trade Summary

Net Seller: 400 shares ($6,400)

Net Sell 4 txns

Insider Lorrain Daniel S.

Role Chief Scientific Officer

Sold 400 shs ($6K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	400	$0.00	--
Exercise	Class A Common Stock	400	$1.01	$404.00
Sale	Class A Common Stock	400	$16.00	$6K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 75,530 shares (Direct); Class A Common Stock — 156,452 shares (Direct); Class A Common Stock — 6,842 shares (Indirect, By Spouse)

Footnotes (1)

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. The stock options are fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/11/2026		M(1)		400	A	$1.01	156,452	D
Class A Common Stock	02/11/2026		S(1)		400	D	$16	156,052	D
Class A Common Stock								6,842	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	02/11/2026		M(1)			400	(2)	02/24/2030	Class A Common Stock	400	$0	75,530	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The stock options are fully vested and exercisable.

	/s/ Peter Slover, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CTNM’s Chief Scientific Officer report on this Form 4?

The Chief Scientific Officer of Contineum Therapeutics reported exercising stock options for 400 Class A shares at $1.01 each and selling 400 Class A shares at $16 on February 11, 2026, under a pre-arranged Rule 10b5-1 trading plan.

How many Contineum Therapeutics (CTNM) shares did the insider sell and at what price?

The insider sold 400 shares of Contineum Therapeutics Class A common stock at $16 per share. This sale occurred on February 11, 2026, immediately after exercising 400 stock options that had an exercise price of $1.01 per share.

What stock options did the CTNM insider exercise in this filing?

The insider exercised 400 stock options, each giving the right to buy one Class A common share at an exercise price of $1.01. These options are fully vested and exercisable, and are part of a larger option position expiring on February 24, 2030.

How many Contineum Therapeutics (CTNM) shares does the insider own after the transactions?

After the reported transactions, the insider directly owns 156,052 shares of Contineum Therapeutics Class A common stock. In addition, 6,842 Class A shares are held indirectly through the insider’s spouse, as disclosed in the ownership table.

What is the significance of the Rule 10b5-1 trading plan mentioned for CTNM’s insider?

The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025. Such plans pre-schedule trades, allowing insiders to sell or exercise shares according to predetermined instructions, helping separate trading decisions from later nonpublic information.

How many stock options does the CTNM insider hold after exercising 400 options?

Following the exercise of 400 stock options, the insider holds 75,530 stock options. These options relate to Contineum Therapeutics Class A common stock, are fully vested and exercisable, and carry an exercise price of $1.01 per share with expiration on February 24, 2030.